Metformin Vitabalans

Metformin, the active ingredient in Metformin Vitabalans, is a biguanide presented as an oral tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus by reducing hepatic glucose production and enhancing peripheral insulin sensitivity, helping lower elevated blood sugar levels in patients who require adjunctive therapy alongside diet and exercise.

GNH USA supplies Metformin Vitabalans as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is indicated for conditions within the type 2 diabetes mellitus therapeutic pathway.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose levels.

Metformin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat, especially after initiation. - Vitamin B12 deficiency: possible decrease with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Severe hypoglycemia: when combined with insulin or sulfonylureas. - Allergic reactions: rash, pruritus, or angioedema.

Before prescribing Metformin Vitabalans, clinicians should consider several safety factors. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: avoid in patients with significant liver disease. - Lactic acidosis risk: discontinue if patient develops severe infection, hypoxia, or acute heart failure. - Vitamin B12 monitoring: consider periodic assessment during long‑term therapy. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Metformin can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast media: may precipitate lactic acidosis; avoid concurrent use. - Alcohol: increases risk of lactic acidosis; advise abstinence. - Other antidiabetic agents (e.g., sulfonylureas, insulin): may cause severe hypoglycemia; monitor closely or adjust dose.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metformin plasma concentrations. - ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment. - Warfarin: may alter INR; monitor coagulation parameters.